Evidence map›Paper›PMID 39099201›Full record

ArticleCancer research communications2024

Role of Forkhead Box P3 in IFNγ-Mediated PD-L1 Expression and Bladder Cancer Epithelial-to-Mesenchymal Transition.

Hanwei Zhang, Ann Ly, Emily Chou, Liang Wang, Paul Zhang, Kris Prado, Yiqian Gu, Matteo Pellegrini, Arnold I Chin

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Hanwei ZhangDepartment of Urology, University of California, Los Angeles, California.ORCID 0009-0001-0340-9819
Ann LyDepartment of Urology, University of California, Los Angeles, California.ORCID 0009-0005-4740-5966
Emily ChouDepartment of Urology, University of California, Los Angeles, California.ORCID 0009-0002-9862-5123
Liang WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, California.ORCID 0000-0002-4052-1316
Paul ZhangDepartment of Molecular, Cell and Developmental Biology, University of California, Los Angeles, California.ORCID 0009-0009-5625-6498
Kris PradoDepartment of Urology, University of California, Los Angeles, California.ORCID 0000-0002-3987-7892
Yiqian GuDepartment of Molecular, Cell and Developmental Biology, University of California, Los Angeles, California.ORCID 0009-0000-9131-6278
Matteo PellegriniDepartment of Molecular, Cell and Developmental Biology, University of California, Los Angeles, California.ORCID 0000-0001-9355-9564
Arnold I ChinDepartment of Urology, University of California, Los Angeles, California.ORCID 0000-0002-6714-9200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antagonism of the PD-1/PD-L1 axis is a critical therapeutic strategy for patients with advanced bladder cancer. IFNγ functions as a key regulator of PD-L1 in both immune as well as cancer cells. Forkhead box P3 (FOXP3) is a transcription factor synonymous in T regulatory cell function but with increasingly described functions in cancer cells. Here, we investigated the relationship between FOXP3 and PD-L1 in bladder cancer. We showed that FOXP3 is critical in the ability for IFNγ to activate PD-L1 in bladder cancer cells. FOXP3 can bind to the PD-L1 promoter and induces a gene program that leads to regulation of multiple immune-related genes and genes involved in epithelial-to-mesenchymal transition (EMT). Using in vitro and in vivo human and murine models, we showed that FOXP3 can influence bladder cancer EMT as well as promote cancer metastases. Furthermore, FOXP3 may be a convergent factor for multiple activators of PD-L1, including the chemotherapeutic drug cisplatin. SIGNIFICANCE: Historically a key transcription factor driving T regulatory cell function, FOXP3 has an increasingly recognized role in cancer cells. In bladder cancer, we defined a novel mechanism whereby FOXP3 mediates the activation of the immune checkpoint PD-L1 by the cytokine IFNγ. We also showed that FOXP3 induces other immune checkpoints as well as genes involved in EMT, promoting immune resistance and cancer metastases.

Indexed as

B7-H1 AntigenEpithelial-Mesenchymal TransitionForkhead Transcription FactorsInterferon-gammaUrinary Bladder NeoplasmsAnimalsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceB7-H1 AntigenCD274 protein, humanCd274 protein, mouseForkhead Transcription FactorsFOXP3 protein, humanFoxp3 protein, mouseInterferon-gamma

Identifiers

PMID39099201
PMCPMC11345674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.